September 9, 2025 – In a strategic move that signals Novartis’ continued commitment to innovation in cardiovascular medicine, Swiss pharmaceutical giant Novartis AG has entered into a definitive agreement to acquire Tourmaline Bio in a deal valued at approximately $1.4 billion. This acquisition is one of the largest bolt-on deals for Novartis in 2025 and comes during a year of intense merger and acquisition (M&A) activity in the global biopharmaceutical sector, with major players racing to secure assets that can drive future growth and address unmet medical needs.

Deal Highlights and Strategic Rationale

The acquisition will give Novartis control over Tourmaline Bio’s lead asset, pacibekitug, a promising therapy for atherosclerotic cardiovascular disease (ASCVD). ASCVD continues to be a leading cause of morbidity and mortality worldwide, with the World Health Organization estimating around 17.9 million deaths globally each year due to cardiovascular diseases (CVDs). Pacibekitug, a monoclonal antibody therapy, targets a specific pathway implicated in the buildup of arterial plaque, a hallmark of ASCVD. The asset is currently in mid- to late-stage clinical trials, with top-line data expected in 2026.

The acquisition aligns with Novartis’ stated strategy of pursuing targeted, high-value deals that complement its core therapeutic areas. According to company executives, Novartis has committed over $17 billion to M&A and licensing activities in 2025 alone, with cardiovascular, neuroscience, and immunology taking center stage in its portfolio refresh. The Tourmaline Bio deal uniquely positions Novartis to expand its development pipeline and maintain leadership in the high-stakes cardiovascular medicine market.

Industry Context: Pharma M&A Heats Up in 2025

Novartis’ Tourmaline Bio buyout reflects a broader trend of consolidation in the biopharma space. After a cautious M&A environment in 2024, market analysts have reported a strong resurgence of deals in 2025, spurred by shifting capital markets dynamics, patent expiries for blockbuster drugs, and a renewed focus on innovative therapies. According to Evaluate Vantage, over $150 billion in deals have been announced in the pharmaceutical industry year-to-date, marking a significant increase from the prior year.

A key driver of dealmaking this year has been the biotechs’ need for capital and larger pharmas’ desire to secure pipelines that can offset imminent losses from generic competition. Large pharmaceutical groups are prioritizing acquisitions in cardiovascular disease, rare diseases, oncology, and neurological disorders, reflecting both the rising burden of chronic diseases and the scientific advances in these domains.

Tourmaline Bio: An Emerging Cardiovascular Contender

Founded in 2020, Tourmaline Bio has quickly gained recognition for its cutting-edge research in cardiovascular therapeutics. Its principal asset, pacibekitug, has shown early signs of efficacy in reducing cholesterol buildup and cardiovascular inflammatory markers, with a favorable safety profile thus far in trials. The treatment holds orphan drug designations in several markets and has generated excitement among industry observers as a potential best-in-class therapy for severe forms of ASCVD.

The acquisition by Novartis is expected to accelerate pacibekitug’s global development and commercialization, leveraging Novartis’ established clinical infrastructure, regulatory expertise, and commercial prowess. Novartis CEO Vas Narasimhan commented, “This acquisition aligns perfectly with our strategy to deliver highly innovative solutions in cardiovascular medicine, where the patient need remains enormous.”

Financial & Market Implications

The $1.4 billion valuation includes a mix of cash and milestone-based payments tied to key developmental and regulatory events. Investors responded positively to the announcement—Tourmaline Bio shares surged by more than 35% in after-hours trading on the day of the deal, while Novartis’ stock remained stable following the news, reflecting investor confidence in the strategic value of this acquisition.

Industry analysts suggest that Novartis’ bet on pacibekitug comes at a time when cardiovascular therapeutics are regaining commercial momentum, driven by new biologic drugs and shifts in treatment paradigms. The worldwide market for cardiovascular drugs is projected to grow to over $80 billion by 2030, according to data from GlobalData and IQVIA. Successful development and commercialization of pacibekitug could tap into a sizable portion of this market, especially given its differentiated approach.

Outlook: Novartis’ Growth Trajectory and Broader Sector Trends

This deal is only one component of Novartis’ robust business development in 2025. In addition to the Tourmaline Bio acquisition, Novartis has taken stakes in other emerging biotechs focusing on RNA therapeutics and gene editing, reflecting a willingness to diversify within key medical frontiers. Globally, competition in the cardiovascular space is also increasing, with Pfizer, Amgen, and AstraZeneca all making parallel moves to strengthen their own late-stage pipelines—often by acquiring innovators or licensing promising clinical candidates.

In a statement, Tourmaline Bio’s CEO expressed optimism about joining Novartis: “Becoming part of Novartis gives our team and our science the best possible platform to quickly and effectively get our lead therapy to the patients who need it most.” The deal is expected to close in Q4 2025, pending customary regulatory approvals.

As the M&A wave continues, 2025 is shaping up as a pivotal year for the life sciences sector, with companies like Novartis demonstrating how strategic deal-making can drive innovation and deliver impact for patients worldwide.